{"id":912,"date":"2014-12-15T13:24:43","date_gmt":"2014-12-15T13:24:43","guid":{"rendered":"http:\/\/library.sath.nhs.uk\/intelligence\/?p=912"},"modified":"2016-10-31T13:26:02","modified_gmt":"2016-10-31T13:26:02","slug":"berep4-and-cd34-immunostaining-distinguishes-basaloid-tricholemmoma-from-basal-cell-carcinoma-2014","status":"publish","type":"post","link":"https:\/\/www.library.sath.nhs.uk\/research\/2014\/12\/15\/berep4-and-cd34-immunostaining-distinguishes-basaloid-tricholemmoma-from-basal-cell-carcinoma-2014\/","title":{"rendered":"BerEP4 and CD34 immunostaining distinguishes basaloid tricholemmoma from basal cell carcinoma  (2014)"},"content":{"rendered":"<p> <strong>Type of publication:<\/strong><br \/> Conference abstract<\/p>\n<p><strong>Author(s):<\/strong><br \/> Turnbull N., Ghumra W., *Mudaliar V., Vella J., Sanders S., Taibjee S., Carr R.<\/p>\n<p><strong>Citation:<\/strong><br \/> American Journal of Dermatopathology, February 2014, vol.\/is. 36\/2(e54-e55), 0193-1091 (February 2014)<\/p>\n<p><strong>Abstract:<\/strong><br \/> Aim: To study of the utility of an immunopanel comprising BerEP4, EMA and CD34 in the differential diagnosis of basaloid tricholemmoma and basal cell carcinoma. Method: An immunopanel comprising BerEP4, EMA and CD34 was applied to 48 tricholemmomas (TL) diagnosed and collected over a 12 year period including 10 tumours with a prominent basaloid component (BTL). Patterns of immunostaining were compared with BCC from our extensive database. Positive immunostaining was defined as moderate to strong intensity in a minimum of 10% of the tumour area. Results: Positivity for BerEP4, EMA and CD34 respectively was as follows: TL &#8211; 1\/24 (4.1%), 4\/21 (19%), 34\/34 (100%), BTL- 2\/9 (22%), 1\/7 (14%), 10\/10 (100%) and BCC &#8211; 218\/219 (99.5%), 10\/199 (5%), 0\/14 (0%). CD34 in TL was often only focally positive (10% in 5\/ 10 cases of BTL). BerEP4 was expressed in at most 20% of the tumour area in basaloid tricholemmomas, but in at least 40% of the tumour area in 95.4% of BCC. Conclusion: Immunostaining for CD34 in combination with BerEP4 helps distinguish BTL from BCC.<\/p>\n<p><strong>Link to more details or full-text: <a href=\"http:\/\/gsia.tums.ac.ir\/images\/UserFiles\/12030\/Forms\/306\/XXXIV_Symposium_of_the_International_Society_of_25.pdf\" target=\"_blank\"><a href=\"http:\/\/gsia.tums.ac.ir\/images\/UserFiles\/12030\/Forms\/306\/XXXIV_Symposium_of_the_International_Society_of_25.pdf\" >http:\/\/gsia.tums.ac.ir\/images\/UserFiles\/12030\/Forms\/306\/XXXIV_Symposium_of_the_International_Society_of_25.pdf<\/a><\/a><\/strong><\/p>\n<p> <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Type of publication: Conference abstract Author(s): Turnbull N., Ghumra W., *Mudaliar V., Vella J., Sanders S., Taibjee S., Carr R. Citation: American Journal of Dermatopathology, February 2014, vol.\/is. 36\/2(e54-e55), 0193-1091 (February 2014) Abstract: Aim: To study of the utility of<span class=\"ellipsis\">&hellip;<\/span><\/p>\n<div class=\"read-more\"><a href=\"https:\/\/www.library.sath.nhs.uk\/research\/2014\/12\/15\/berep4-and-cd34-immunostaining-distinguishes-basaloid-tricholemmoma-from-basal-cell-carcinoma-2014\/\">Read more <span class=\"screen-reader-text\">BerEP4 and CD34 immunostaining distinguishes basaloid tricholemmoma from basal cell carcinoma  (2014)<\/span><span class=\"meta-nav\"> &#8250;<\/span><\/a><\/div>\n<p><!-- end of .read-more --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[200],"tags":[458,255],"class_list":["post-912","post","type-post","status-publish","format-standard","hentry","category-staff-publication","tag-458","tag-cancer"],"_links":{"self":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/comments?post=912"}],"version-history":[{"count":1,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/912\/revisions"}],"predecessor-version":[{"id":1477,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/posts\/912\/revisions\/1477"}],"wp:attachment":[{"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/media?parent=912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/categories?post=912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.library.sath.nhs.uk\/research\/wp-json\/wp\/v2\/tags?post=912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}